|
|
Article: AstraZeneca, GSK Explain Plans To 'Externalize' Work.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
SAN FRANCISCO - Pharma's growing desperation for viable drugs became ever more clear at the Allicense meeting here, as officials from two major players, AstraZeneca plc and GlaxoSmithKline plc, provided a somewhat more detailed peek than usual into their strategies.
"We know the innovation is sitting in this room," said Johan Hoegstedt, in charge of North American strategic planning and business development for AstraZeneca, adding that it's "no surprise to any of you that we have had some disappointments in late-stage products."
Notable among them is Galida (tesaglitazar), a dual-acting oral peroxisome proliferator-activated ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|